- 1601. dextromethorphan
- [A synthetic, methylated dextrorotary analogue of levorphanol, a substance related to codeine and a non-opioid derivate of morphine. Dextromethorphan exhibits antitussive activity and is devoid of analgesic or addictive property. This agent crosses the blood-brain-barrier and activates sigma opioid receptors on the cough center in the central nervous system, thereby suppressing the cough reflex. ( NCI )] (UMLS (CSP) C0011816) =Organic Chemical; Pharmacologic Substance ;
=LEVORPHANOL;
morphinan;
[RE302] NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;
=DEXTROMETHORPHAN HYDROBROMIDE;
Dextromethorphan 1 MG/ML;
Dextromethorphan 1.5 MG/ML;
DEXTROMETHORPHAN 15 MG;
DEXTROMETHORPHAN 15 MG/5ML;
DEXTROMETHORPHAN 60 MG;
DEXTROMETHORPHAN 30 MG;
DEXTROMETHORPHAN 25 MG/5ML;
| - 1651. DHAD/TOPO/TSPA
- (UMLS (NCI) C0678042) =Therapeutic or Preventive Procedure ;
|
- 1602. Dextropropoxyphene Hydrochloride
- [The hydrochloride salt form of dextropropoxyphene, the d-isomer of propoxyphene, a synthetic diphenyl propionate derivative, with narcotic analgesic effect. Mimics the effects of endogenous opiates, dextropropoxyphene, binds to mu receptors located throughout the central nervous system. The binding results in GTP to GDP exchanges on the mu-G-protein complex, through which inactivates effector adenylate cyclase thereby decreases intracellular cAMP. This inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin and somatostatin. In addition, dextropropoxyphene closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels. This results in hyperpolarization, thereby reducing neuronal excitability which further decreases the perception of pain. ( NCI )] (UMLS (NCI) C0242451) =Organic Chemical; Pharmacologic Substance =PROPOXYPHENE;
Propoxyphene Napsylate =PROPOXYPHENE HYDROCHLORIDE 65 MG;
PROPOXYPHENE HYDROCHLORIDE 32 MG;
| - 1652. DHAD/TSPA
- (UMLS (NCI) C0280683) =Therapeutic or Preventive Procedure
|
- 1603. Dextrose Anhydrous
- [The anhydrous form of D-glucose, a natural monosaccharide and carbohydrate. Dextrose serves to replenish lost nutrients and electrolytes. The agent provides metabolic energy and is the primary ingredient in oral rehydration salts (ORS) and is used in intravenous (IV) fluids to provide nutrients to patients under intensive care who are unable to receive them by the oral route. Solutions containing dextrose restore blood glucose levels and provide calories and may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose anhydrous also plays a role in the production of proteins and in lipid metabolism. ( NCI )] (UMLS (NCI) C1165353) DEXTROSE, ANHYDROUS =Carbohydrate; Pharmacologic Substance
| - 1653. DHAD/TSPA/VP-16
- (UMLS (NCI) C0280523) =Therapeutic or Preventive Procedure
|
- 1604. DEXTROTHYROXINE
- [The dextrorotary isomer of thyroxine, a thyroid hormone with antihyperlipidemic activity. Dextrothyroxine stimulates the formation of low-density lipoprotein (LDL) and increases the catabolism of LDL thereby leading to increased excretion of cholesterol and bile acids via the biliary route. This results in a reduction in serum cholesterol and LDL. ( NCI )] (UMLS (NCI) C0011824) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Hormone =[CV350] ANTILIPEMIC AGENTS;
Levothyroxine =DEXTROTHYROXINE SODIUM;
| - 1654. DHAD/VNB
- (UMLS (NCI) C0677974) =Therapeutic or Preventive Procedure
|
- 1605. Dexverapamil
- [The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. (NCI04) ( NCI )] (UMLS (NCI) C0280858) =Organic Chemical; Pharmacologic Substance
| - 1655. DHAD/VP-16
- (UMLS (NCI) C0279049) =Therapeutic or Preventive Procedure
|
- 1606. Dexverapamil/Doxorubicin
- (UMLS (NCI) C0281757) =Therapeutic or Preventive Procedure
| - 1656. DHE
- [The purified component of HEMATOPORPHYRIN DERIVATIVE, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (HEMATOPORPHYRIN PHOTORADIATION); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of PHOTODYNAMIC THERAPY in the United States. ( MSH )] (UMLS (NCI) C0058031) =Organic Chemical; Pharmacologic Substance ;
|
- 1607. Dexverapamil/Paclitaxel
- (UMLS (NCI) C0281326) =Therapeutic or Preventive Procedure
| - 1657. DHE/OMEP
- (UMLS (NCI) C0678018) =Therapeutic or Preventive Procedure
|
- 1608. Dexverapamil/Vinblastine
- (UMLS (NCI) C0281668) =Therapeutic or Preventive Procedure
| - 1658. DHEA Analog 8354
- (UMLS (NCI) C0539514) =Steroid; Pharmacologic Substance ;
|
- 1609. Dezocine
- (UMLS (NCI) C0057626) =Organic Chemical; Pharmacologic Substance ;
=[CN101] OPIOID ANALGESICS;
Cycloparaffins | - 1659. Dhegiha
- (UMLS (HL7) C1699696) =Language =MississippiValley;
=Osage;
Omaha-Ponca;
Kansa;
Alkansea;
|
- 1610. Dezone
- (UMLS (NCI) C0701257) =Steroid; Pharmacologic Substance ;
| - 1660. DHFR
- [Dihydrofolate reductase converts dihydrofolate into tetrahydrofolate, a methyl group shuttle required for the de novo synthesis of purines, thymidylic acid, and certain amino acids. It is a drug target. Variation in gene expression or sequence may alter the efficacy of chemotherapy. (from LocusLink and NCI) ( NCI )] (UMLS (NCI) C0039667) =Amino Acid, Peptide, or Protein; Enzyme ;
=amine oxidoreductase;
Genes, Reporter |
- 1611. dFdC/5-FU
- (UMLS (NCI) C0392944) =Therapeutic or Preventive Procedure
| - 1661. DHFR
- [This gene is involved in biosynthesis, nucleotide metabolism and the immune response. ( NCI )] (UMLS (NCI) C1333216) DHFR Gene;
Dihydrofolate Reductase Gene =Gene or Genome ;
|
- 1612. DFdC/5-FU/IFN-A/IL-2
- (UMLS (NCI) C0796440) Fluorouracil/Gemcitabine/Interferon Alfa/Interleukin-2 =Therapeutic or Preventive Procedure ;
| - 1662. DHFR Inhibitor
- [Substances that inhibit Dihydrofolate Reductase interfering with the conversion of Dihydrofolate to Tetrahydrofolate, causing inhibition of nucleotide biosynthesis and protein synthesis. ( NCI )] (UMLS (NCI) C1373048) Dihydrofolate Reductase Inhibitor;
Dihydrofolate Reductase Inhibitors;
=Pharmacologic Substance ;
=antifolate;
|
- 1613. dFdC/DOX
- (UMLS (NCI) C0677788) =Therapeutic or Preventive Procedure
| - 1663. DHODH
- [This gene plays a role in pyrimidine metabolism. ( NCI )] (UMLS (NCI) C1333217) DHODH Gene;
Dihydroorotate Dehydrogenase Gene =Gene or Genome ;
|
- 1614. dFdC/MOAB HER2
- (UMLS (NCI) C0796529) Gemcitabine/Monoclonal Antibody HER2;
Gemcitabine/Trastuzumab;
Trastuzumab/Gemcitabine =Therapeutic or Preventive Procedure ;
| - 1664. Dhori virus
- [ ] (UMLS (CSP) C0206549) =Virus
|
- 1615. dFdC/R115777
- (UMLS (NCI) C0796468) Gemcitabine/R115777;
Gemcitabine/Tipifarnib;
=Therapeutic or Preventive Procedure | - 1665. DHP
- [partially saturated derivative of pyridine; binds to and inhibits the voltage-gated calcium channel of skeletal muscle T junctional membranes, the principle molecular transducer of excitation-contraction coupling. ( CSP )] (UMLS (CSP) C0220821) =Organic Chemical; Pharmacologic Substance ;
=[CV200] CALCIUM CHANNEL BLOCKERS;
pyridine |
- 1616. dFdC/TAX
- (UMLS (NCI) C0796302) Gemcitabine/Paclitaxel =Therapeutic or Preventive Procedure ;
| - 1666. DHPG sodium
- [The sodium salt form of ganciclovir, a synthetic, antiviral, purine nucleoside analog with antiviral activity, especially against cytomegalovirus (CMV). Ganciclovir sodium is a prodrug that is phosphorylated and subsequently converted into its triphosphate form, the active metabolite ganciclovir-5-triphosphate (ganciclovir-TP), in the infected cells by cellular kinases. Ganciclovir-TP competes as a substrate with nucleotide triphosphates for viral DNA polymerase. Once it gets incorporated into DNA strand, it prevents further polymerization of DNA, thereby interfering with viral DNA replication. ( NCI )] (UMLS (NCI) C0282399) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
=2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one;
=GANCICLOVIR (AS SODIUM) 500;
GANCICLOVIR (AS SODIUM) 250 MG |
- 1617. dFdC/TOPO
- (UMLS (NCI) C0678102) =Therapeutic or Preventive Procedure
| - 1667. Di-Adreson-F
- (UMLS (NCI) C0699539) =Steroid; Pharmacologic Substance
|
- 1618. dFdC/VNB
- [A regimen consisting of vinorelbine and gemcitabine, used as a salvage regimen for relapsed, childhood Hodgkin's lymphoma, following an autologous hematopoietic stem cell transplant. ( NCI )] (UMLS (NCI) C0796306) Gemcitabine/Vinorelbine;
Vinorelbine-Gemcitabine;
Vinorelbine-Gemcitabine Regimen =Therapeutic or Preventive Procedure ;
| - 1668. Di-dgA-RFB4 Immunotoxin
- [An anticancer drug that is a combination of a monoclonal antibody (RFB4) and an immunotoxin (dgA). ( NCI )] (UMLS (NCI) C0677768) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
|
- 1619. dFdC/VP-16
- (UMLS (NCI) C0678084) =Therapeutic or Preventive Procedure
| - 1669. DIA (differentiation inhibiting activity)
- [ ] (UMLS (CSP) C0113865) =Amino Acid, Peptide, or Protein; Immunologic Factor
|
- 1620. DFMO/DOX/IFN-A
- (UMLS (NCI) C0338087) =Therapeutic or Preventive Procedure
| - 1670. diabetes amputation
- [ ] (UMLS (CSP) C0598284) =Therapeutic or Preventive Procedure
|
- 1621. DFMO/IFN-A
- (UMLS (NCI) C0338096) =Therapeutic or Preventive Procedure
| - 1671. diabetes bronze
- [condition in which there is a deviation or interruption in the storage of iron in the body. ( CSP )] (UMLS (CSP) C0018995) =Disease or Syndrome =DIS IRON METABOLISM;
inborn metal metabolism disorder;
iron overload;
=hemosiderosis;
|
- 1622. DFMO/MGBG
- (UMLS (NCI) C0280648) =Therapeutic or Preventive Procedure
| - 1672. diabetes education
- [instruction or training that encourages behaviors most likely to optimize health potentials through information about diabetes; facilitates the prevention of diabetes, frequently for those who are at risk for developing diabetes; also includes instruction or training that increases the awareness and favorably influences the attitudes and knowledge about diabetes on a personal or community basis; it also includes the training of medical personnel about diabetes for prevention or treatment programs, for this type of diabetes education postcoordinate with the appropriate health professional education term. ( CSP )] (UMLS (CSP) C0850356) =Educational Activity =health education;
|
- 1623. DFMO/PXM
- (UMLS (NCI) C0281306) =Therapeutic or Preventive Procedure ;
| - 1673. Diabetes Educator
- (UMLS (HL7) C1555973) =Intellectual Product =Registered Nurse;
|
- 1624. DFP
- [irreversible cholinesterase inhibitor with actions similar to those of echothiophate; it is a powerful miotic used mainly in the treatment of glaucoma; its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. ( CSP )] (UMLS (CSP) C0022181) =Organophosphorus Compound; Pharmacologic Substance; Hazardous or Poisonous Substance =cholinesterase inhibitor;
Organophosphorus Compounds;
alkylphosphate;
[OP102] MIOTICS, TOPICAL OPHTHALMIC | - 1674. DIABETES IN PREG-UNSPEC
- [ ] (UMLS (ICD9CM) C0341893) =Disease or Syndrome
|
- 1625. DFT/ACK - Post detail financial transaction
- (UMLS (HL7) C1549275) =Health Care Activity =Event Type;
| - 1675. Diabetes in Pregnancy
- [glucose intolerance which onsets during pregnancy; does not include diabetics who become pregnant or women who become lactosuric; after pregnancy, the woman is reclassified as diabetic or not depending on whether glucose intolerance persists. ( CSP )] (UMLS (NCI) C0085207) =Disease or Syndrome ;
=Diabete mellito;
Pregnancy Complication;
Pregnancy Disorder;
=fetal macrosomia |
- 1626. DFT/ACK - Post Detail Financial Transactions - New
- (UMLS (HL7) C1549283) =Health Care Activity =Event Type;
| - 1676. diabetes insipidus
- [metabolic disorder due to injury of the neurohypophyseal system; results in deficient quanity of antidiuretic hormone being released or produced, failure of tubular reabsorption of water in the kidney. ( CSP )] (UMLS (CSP) C0011848) =Disease or Syndrome =hypopituitarism;
Metabolic Disease =Diabetes Insipidus, Nephrogenic;
Wolfram syndrome;
Diabetes Insipidus, Nephrogenic;
antidiuretic hormone defective syndrome |
- 1627. dGTPase
- [Deoxyguanosine triphosphate (dGTP) triphosphohydrolase (EC 3.1.5.1). Highly specific for dGTP, producing deoxyguanosine and inorganic tripolyphosphate. (Seto et al, JBC 1988) ( NCI )] (UMLS (NCI) C0057631) =Amino Acid, Peptide, or Protein; Enzyme ;
| - 1677. Diabetes mellitus
- [heterogeneous group of disorders that share glucose intolerance in common.(CSP)] (UMLS (ICPC) C0011849) (Diabetes mellitus; DIABETES MELITUSA; Diabetes mellitus; Diabetes mellitus; SOKERITAUTI; Diabete sucre; Diabetes mellitus; sukeret; diabetes mellitus; Diabete mellito; SUKKERSYKE/DIABETES MELLITUS; Diabetes mellitus; Diabetes mellitus; DIABETES MELLITUS/SOCKERSJUKA) =Disease or Syndrome =Endocrine Disease; Metabolic Disease; Endocrine Pancreas Disease; ENDOCRINE, METABOLIC AND NUTRITIONAL; Diagnosis/Diseases Component; =Diabetes Mellitus, Insulin-Dependent; adult onset diabetes mellitus; Diabetic Angiopathies; Diabetes with ketoacidosis; Diabetes with renal manifestations; Diabetes with neurological manifestations; Diabetes in Pregnancy; drug related diabetes mellitus; prediabetic state; virus related diabetes mellitus; diabetic cardiomyopathy; diabetic ophthalmopathy; Diabetes Mellitus, Experimental; Diabetes Mellitus, Insulin-Dependent; Diabetes Mellitus, Lipoatrophic; adult onset diabetes mellitus; Diabetic Angiopathies; Diabetes with ketoacidosis; Diabetes with renal manifestations; Diabetes with neurological manifestations; Obesity in Diabetes; Diabetes mellitus, antepartum; Diabetes in Pregnancy; prediabetic state; diabetic coma;
|
- 1628. DHA-Paclitaxel
- [A combination of DHA (a natural fatty acid) and paclitaxel (an anticancer drug) that is being studied as a treatment for cancer. ( NCI )] (UMLS (NCI) C1134470) Docosahexaenoic Acid-Paclitaxel conjugate;
TXP =Organic Chemical; Pharmacologic Substance ;
| - 1678. diabetes mellitus diet
- [A diet that uses carbohydrates sparingly. Typically with a restriction in daily energy content (e.g. 1600-2000 kcal). ( HL7V3.0 )] (UMLS (HL7) C1550566) =Intellectual Product =Diet;
|
- 1629. DHA-Paclitaxel/Gemcitabine
- (UMLS (NCI) C1327871) =Therapeutic or Preventive Procedure ;
| - 1679. diabetes mellitus genetics
- [heredity of diabetes mellitus, especially the mechanisms of hereditary transmission and the variation of inherited characteristics of diabetes mellitus; the genetic constitution of an individual as it relates to diabetes mellitus. ( CSP )] (UMLS (CSP) C0596425) =Occupation or Discipline =Genetics;
|
- 1630. DHAC
- [A synthetic nucleoside analogue of deoxycytidine. Dihydro-5-azacytidine inhibits DNA methyltransferase, thereby interfering with abnormal DNA methylation patterns that are associated with genetic instability in some tumor cells. Inhibition of this enzyme may restore expression of tumor-suppressor genes and result in antitumor activity. (NCI04) ( NCI )] (UMLS (NCI) C0048906) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
| - 1680. diabetes mellitus nursing
- [ ] (UMLS (CSP) C0599003) =Biomedical Occupation or Discipline ;
|
- 1631. DHAD/5-FU/MTX
- (UMLS (NCI) C0083765) =Therapeutic or Preventive Procedure ;
| - 1681. Diabetes mellitus of mother, with delivery
- [ ] (UMLS (ICD9CM) C0341897) =Disease or Syndrome
|
- 1632. DHAD/FAMP
- (UMLS (NCI) C0281747) =Therapeutic or Preventive Procedure
| - 1682. Diabetes mellitus of mother, with delivery, with mention of postpartum complication
- [ ] (UMLS (ICD9CM) C0341896) =Disease or Syndrome
|
- 1633. DHAD/GM-CSF
- (UMLS (NCI) C0279103) =Therapeutic or Preventive Procedure
| - 1683. diabetes mellitus therapy
- [ ] (UMLS (CSP) C0948092) =Therapeutic or Preventive Procedure =Therapeutic Interventions;
=artificial endocrine pancreas |
- 1634. DHAD/GM-CSF/VP-16
- (UMLS (NCI) C0281674) =Therapeutic or Preventive Procedure
| - 1684. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with neurological manifestations
- [ ] (UMLS (ICD9CM) C0375138) =Disease or Syndrome
|
- 1635. DHAD/HC
- (UMLS (NCI) C0281308) =Therapeutic or Preventive Procedure ;
| - 1685. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with ophthalmic manifestations
- [ ] (UMLS (ICD9CM) C0375135) =Disease or Syndrome
|
- 1636. DHAD/IFF
- (UMLS (NCI) C0280505) =Therapeutic or Preventive Procedure ;
| - 1686. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with other specified manifestations
- [ ] (UMLS (ICD9CM) C0375146) =Disease or Syndrome
|
- 1637. DHAD/IFF/mesna
- (UMLS (NCI) C0393048) =Therapeutic or Preventive Procedure
| - 1687. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with peripheral circulatory disorders
- [ ] (UMLS (ICD9CM) C0375142) =Disease or Syndrome
|
- 1638. DHAD/IFF/mesna/VP-16
- (UMLS (NCI) C0338297) =Therapeutic or Preventive Procedure
| - 1688. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with renal manifestations
- [ ] (UMLS (ICD9CM) C0375131) =Disease or Syndrome
|
- 1639. DHAD/IFF/VP-16
- (UMLS (NCI) C0280689) =Therapeutic or Preventive Procedure
| - 1689. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with unspecified complication
- [ ] (UMLS (ICD9CM) C0375150) =Disease or Syndrome
|
- 1640. DHAD/IFN-A
- (UMLS (NCI) C0338108) =Therapeutic or Preventive Procedure ;
| - 1690. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], uncontrolled, with unspecified complication
- [ ] (UMLS (ICD9CM) C0375152) =Disease or Syndrome
|
- 1641. DHAD/L-ATRA/VP-16
- (UMLS (NCI) C0338224) =Therapeutic or Preventive Procedure
| - 1691. Diabetes mellitus type I [juvenile type], uncontrolled, with neurological manifestations
- [ ] (UMLS (ICD9CM) C0375140) =Disease or Syndrome
|
- 1642. DHAD/L-PAM
- (UMLS (NCI) C0392932) =Therapeutic or Preventive Procedure ;
| - 1692. Diabetes mellitus type I [juvenile type], uncontrolled, with ophthalmic manifestations
- [ ] (UMLS (ICD9CM) C0375136) =Disease or Syndrome
|
- 1643. DHAD/MGBG/VBL/VP-16
- (UMLS (NCI) C0280467) =Therapeutic or Preventive Procedure
| - 1693. Diabetes mellitus type I [juvenile type], uncontrolled, with other specified manifestations
- [ ] (UMLS (ICD9CM) C0375148) =Disease or Syndrome
|
- 1644. DHAD/PCB/PRED/VCR
- (UMLS (NCI) C0255600) =Therapeutic or Preventive Procedure
| - 1694. Diabetes mellitus type I [juvenile type], uncontrolled, with peripheral circulatory disorders
- [ ] (UMLS (ICD9CM) C0375144) =Disease or Syndrome
|
- 1645. DHAD/PM/VP-16
- (UMLS (NCI) C0279110) =Therapeutic or Preventive Procedure
| - 1695. Diabetes mellitus type I [juvenile type], uncontrolled, with renal manifestations
- [ ] (UMLS (ICD9CM) C0375133) =Disease or Syndrome
|
- 1646. DHAD/PRED
- (UMLS (NCI) C0678009) =Therapeutic or Preventive Procedure
| - 1696. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with neurological manifestations
- [ ] (UMLS (ICD9CM) C0375137) =Disease or Syndrome
|
- 1647. DHAD/PRED/VCR/VP-16
- (UMLS (NCI) C0281404) =Therapeutic or Preventive Procedure ;
| - 1697. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with ophthalmic manifestations
- [ ] (UMLS (ICD9CM) C0375134) =Disease or Syndrome
|
- 1648. DHAD/PSC 833/VP-16
- (UMLS (NCI) C0281726) =Therapeutic or Preventive Procedure
| - 1698. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with other specified manifestations
- [ ] (UMLS (ICD9CM) C0375145) =Disease or Syndrome
|
- 1649. DHAD/TAX
- (UMLS (NCI) C0281593) =Therapeutic or Preventive Procedure
| - 1699. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with peripheral circulatory disorders
- [ ] (UMLS (ICD9CM) C0375141) =Disease or Syndrome
|
- 1650. DHAD/TAX/TSPA
- (UMLS (NCI) C0281473) =Therapeutic or Preventive Procedure
| - 1700. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with renal manifestations
- [ ] (UMLS (ICD9CM) C0375130) =Disease or Syndrome
|
home
